April 25th 2024
In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Countywide Physician Organization Learning Collaborative and Changes in Hospitalization Rates
The University of Best Practices physician organization learning collaborative in San Diego County was associated with lower hospitalization rates for heart attacks.
Read More
Lower LDL Cholesterol Associated With Higher Mortality in American Indians
October 11th 2017Excessively low levels of low-density lipoprotein cholesterol and triglycerides is associated with a higher all-cause mortality among American Indians, according to a new study published online ahead of print in Journal of Diabetes and Its Complications.
Read More
Dr Simon Gibbs Discusses the Future of Pulmonary Hypertension Treatments
October 3rd 2017Current drugs for pulmonary hypertension treat 3 pathways, but currently there aren't any new drugs to treat different pathways, although there likely will be some in the future, said Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.
Watch
Dr Steven Nissen Argues for Aggressively Lowering LDL Cholesterol
October 1st 2017There is an ongoing debate about how aggressively to lower low-density lipoprotein (LDL) cholesterol, but Steve Nissen, MD, of Cleveland Clinic, argues that studies have shown an aggressive approach to lowering LDL always shows benefits.
Watch
Dr Jeanette Stingone on Lasting Cardiovascular Effects of Prenatal Exposure to Air Pollution
September 7th 2017Researchers have known for years: what happens to mom in pregnancy affects the baby. That holds true with prenatal exposure to air pollution, which has lingering cardiovascular effects, such as birth defects and a higher risk of obesity, explained Jeanette Stingone, PhD, of Mount Sinai Health System.
Watch
This Week in Managed Care: September 1, 2017
September 1st 2017This week, the top managed care stories included responses to the disaster in Houston after Hurricane Harvey; the approval of the first gene therapy in the United States; and a new cardiovascular indication for a popular drug to treat type 2 diabetes.
Watch
Study in Lancet Challenges Diet Wisdom About Fat, Vegetables
August 30th 2017The findings will likely add to the controversy over the US dietary guidelines. Lobbyists for grain interests have long been accused of having undue influence in food policy, especially over the now-discarded "food pyramid."
Read More
Dr John Eikelboom: COMPASS' Rivaroxaban Plus Aspirin Will Become Standard for CAD, PAD
August 29th 2017The rivaroxaban plus aspirin combination therapy to treat patients with stable coronary or peripheral artery disease showed such benefits in the COMPASS trial that it should become the standard of care, said John Eikelboom, MBBS, MSc, FRCPC, associate professor at McMaster University.
Watch
Dr Deepak Bhatt Highlights COMPASS Trial Results
August 28th 2017The results of the COMPASS trial testing rivaroxaban plus aspirin in patients with coronary artery disease or peripheral artery disease showed such significant benefits for reducing ischemic events that it was stopped early, explained Deepak Bhatt, MD, MPH, of Brigham and Women's Hospital and Harvard Medical School.
Watch
An Eye on Cardiovascular Prevention: Begin in Childhood, Identify All Risk Factors
August 27th 2017For each level of cardiovascular risk, lifestyle factors remain a significant contributor that can be modified to reduce risk. However, some risk will remain nonmodifiable and require therapy, according to panelists during a session on cardiovascular prevention at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.
Read More
COMPASS: Rivaroxaban Plus Aspirin Protects Against Heart Attack, Stroke
August 27th 2017Rivaroxaban plus aspirin has significant benefits for patients with peripheral artery disease (PAD) and stable coronary artery disease, according to the results of the COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial, presented at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.
Read More
Dr Steven Nissen Outlines New Treatments in Cardiovascular Medicine
August 26th 2017Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.
Watch
Liraglutide Gains New Indication for Reducing CV Event Risk
August 25th 2017Novo Nordisk announced that its diabetes drug liraglutide (Victoza) has been approved by the FDA for a new indication: it can reduce the risk of major cardiovascular (CV) events in patients with type 2 diabetes (T2D) and existing CV disease.
Read More
Continued Statin Use Following Adverse Reaction May Reduce Incidence of Death and CVD Events
July 30th 2017Patients often stop statin treatment following an adverse reaction; however, new research finds an association between continued statin prescriptions after an adverse reaction and a decreased incidence of death and cardiovascular events.
Read More
Study Finds ACOs Have No Meaningful Impact on Medication Use or Adherence
July 25th 2017Many accountable care organizations participating in the Medicare Shared Savings Program focus on disease control and medication use, but a new study published in JAMA Cardiology has found that the programs have not made any meaningful changes in medication use or adherence.
Read More